Navigation Links
Ohr Pharmaceutical Announces Results from OHR/AVR118 Phase II Trial in Cancer Cachexia
Date:3/21/2013

NEW YORK, March 21, 2013 /PRNewswire/ -- Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life. Cancer cachexia is most pronounced in advanced malignancies such as lung, pancreatic and gastrointestinal cancers. There is currently no FDA approved therapy for cancer cachexia.

Eighteen enrolled patients, three with stage III and fifteen with stage IV cancers completed the treatment protocol. The group consisted of six with pancreatic cancer, five with lung cancer, two with prostate cancer and one each with colon, stomach, esophageal, liver cancers and multiple myeloma. While the primary trial end point of weight gain was not achieved, at the completion of treatment, patients achieved stabilization of body weight, body fat and muscle mass with a significant increase in appetite (p=.001).  Moreover, PG-SGA (Patient Generated Subjective Global Assessment) scores demonstrated improvement (p=.025), indicating an enhanced quality of life (QOL).  No statistically significant differences from baseline (as indicated by the paired t test) were observed in body fat content, arm circumference, triceps fold measurement, nausea or vomiting.

Patients had the option to continue receiving study drug after completing the initial 28 day treatment period if they and their doctor felt it was in their best interest, and 11 of the 18 patients (61%) elected to do so, being treated with th
'/>"/>

SOURCE Ohr Pharmaceutical
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Galderma, One of the Leading Pharmaceutical Companies, Relies on Verizon Enterprise Solutions to Provide Expanded, Secure Global Communications Platform
2. ENCO Pharmaceutical Development Announces Another Successful FDA Inspection - Its 2nd This Year
3. First Patients Dosed in Proof-of-Concept Clinical Study of Alder Biopharmaceuticals Lead Therapeutic Candidate for Treatment of Migraine, ALD403
4. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
5. Tech Coast Angels Contributes More Than $3 Million to $16 Million Savara Pharmaceuticals Series B
6. Financial Assessment of the Global Pharmaceutical and Biotechnology Industry
7. Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc.
8. National Pharmaceutical Council Survey Shows Health Care Stakeholders Continue to Show Optimism About the Future Role of Comparative Effectiveness Research
9. Pharmaceutical Distribution Agreement Between Cardinal Health And Walgreens To End August 2013
10. Star Scientific and Rock Creek Pharmaceuticals Report on the Beneficial Nutritional Effects of Anatabine in an Animal Model of Ulcerative Colitis
11. Research-based Pharmaceutical Industry and International Federation of Red Cross and Red Crescent Societies Join Forces to Prevent Non-Communicable Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... , July 10, 2014 Yesterday, former ... (Moberg) medical device manufacturing facility. Rep. Kennedy and ... neurological monitors facilitate cutting-edge research in neurological disease ... and mental health advocate, Garen Staglin , ... to fostering fundamental changes that will radically accelerate ...
(Date:7/10/2014)... , July 10, 2014  Decision Resources ... surveyed infectious disease (ID) specialists are willing to ... Orbactiv (oritavancin) for use as OPAT, approximately two-thirds ... these agents to their hospital inpatients. However, our ... OPAT patients are initiated on OPAT following hospital ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... Terumo Heart, Inc. announced,today that they have ... Drug,Administration (FDA) to begin enrollment in the ... for a Bridge-to-Transplant (BTT) indication., (Logo: ... http://www.newscom.com/cgi-bin/prnh/20080303/CLM012 ), Dr. David Munjal, ...
... 29 Eisai Corporation of,North America, a wholly-owned ... the Food and Drug Administration (FDA) has accepted ... short-term (up to,eight weeks) treatment of gastroesophageal reflux ... indicated that the sNDA will receive,priority review in ...
Cached Medicine Technology:DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial 2FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents 2
(Date:7/12/2014)... 2014 Doylestown Hospital recently conducted an ... men’s health questions. Paddock tackles topics including main ... women live longer than men, and testosterone replacement therapy, ... Simple featured on Doylestown Hospital’s website, Dr. Brad ... any age. If you notice pain, bulging, or asymmetry ...
(Date:7/12/2014)... 12, 2014 Dubai is buzzing with ... is heading to the UAE. The National Basketball ... be in the UAE from 28-31 October to lead ... of diabetes awareness. The event is being organized by ... event management company based in Dubai. The announcement was ...
(Date:7/12/2014)... 12, 2014 Wright & Schulte LLC, an ... Just For Men Lawsuits (case #59776/2014), announces they have ... reports that allege the popular hair dye, Just For Men, ... their face, neck and other areas. In addition to detailing ... chemical burns , the advertisements being run by Wright & ...
(Date:7/12/2014)... Maxim Peptide, a website that features ... solely in scientific experiments, is currently celebrating its second ... Maxim Peptide, which was created by the founders of ... updated website that now features a special deals section. ... with fascinating articles about peptide research, including a new ...
(Date:7/11/2014)... Recently, MagicQuinceaneraDresses.com, the popular online supplier of special occasion ... Quinceanera dresses . The company’s new items are specially ... paying a large amount of money. They are all ... The company’s online shop has become a one stop ... In addition to exquisite Quinceanera dresses, it also offers ...
Breaking Medicine News(10 mins):Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... Member Adds Operations and Marketing Expertise During a Key ... Growth Period for the Association, ... announced the appointment of Susan Trainer, chief executive,officer and founder, Trainer ... at a pivotal time for the Y, which,is in the middle ...
... While urinary stents and,catheters can be life-saving medical ... infections. With 100 million placed in patients each ... device-associated infections,annually. Nerites Corporation is testing its unique ... from a $100,000 small,business innovation research grant (SBIR) ...
... NASDAQ: CRME TSX: COM, VANCOUVER and DEERFIELD, IL, ... TSX: COM) and its co-development partner,Astellas Pharma US, Inc. ... U.S. Food and Drug Administration (FDA) that a decision ... (NDA) for KYNAPID(TM),(vernakalant hydrochloride). The FDA did not provide ...
... and Drug Administration as a palliative treatment for cancer ... sometimes used off-label for the treatment of peripheral vascular ... American Journal of Therapeutics finds that off-label use of ... adverse events and device malfunctions associated with the use ...
... COVER: "The Party,s Over" (p. 22). Editor-at-Large Evan ... in a precarious state. But the party,s,candidates can ... late to reinvent,the party,s core beliefs," writes Thomas. ... humble mission: to show, in effect, some humility. ...
... million Americans, most of them women, suffer from lupus, ... bodys own tissue. This week marks a significant step ... online publication of four new studies identifying genes involved ... K.Crow, M.D., associate chief of the division of Rheumatology ...
Cached Medicine News:Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 2Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 3Health News:Mount Diablo Region YMCA Names Local Business Leader, Susan Trainer, to Its Corporate Executive Board 4Health News:Cardiome And Astellas Announce Regulatory Update 2Health News:Cardiome And Astellas Announce Regulatory Update 3Health News:Cardiome And Astellas Announce Regulatory Update 4Health News:Study looks at off-label use of biliary stents 2Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 2Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 3Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 4Health News:NEWSWEEK: Media Lead Sheet/January 28, 2008 Issue (on newsstands Monday, January 21). 5Health News:NEJM editorial on significance and limitations of new lupus gene expression research 2Health News:NEJM editorial on significance and limitations of new lupus gene expression research 3Health News:NEJM editorial on significance and limitations of new lupus gene expression research 4
... BladderScan® BVI 6100 is a handheld, noninvasive ... is easy to operate, so any staff ... To view ultrasound images from exams and ... records and reimbursement, just log on to ...
... Contigen Bard Collagen Implant, the world's ... implant option for the treatment of Stress ... bulk to surrounding urethral tissue to aid ... with the body's own structure, Contigen Bard ...
... Prosthesis,The AMS DURA II ... of cobalt-chrome alloy strands ... gives patients what they ... positioning, cosmetic concealment and ...
... advanced three-part inflatable prosthesis consisting of a reservoir ... the scrotum and a pair of cylinders inserted ... look and performance of a natural erection. The ... AMS 700 Series now features the new Tactile ...
Medicine Products: